Search Results - "Koukakis, Reija"

Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial by Hirata, Koichi, Takeshima, Takao, Sakai, Fumihiko, Numachi, Yotaro, Yoshida, Ryuji, Koukakis, Reija, Hasebe, Miki, Yui, Daishi, da Silva Lima, Gabriel Paiva, Cheng, Sunfa

“…ObjectivesTo evaluate the 1-year efficacy and safety of once-monthly erenumab 70 mg following a 24-week double-blind treatment period (DBTP) of a phase III…”
Get full text

Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open‐label, multiple‐dose study by Hershey, Andrew D., Paiva da Silva Lima, Gabriel, Pannacciulli, Nicola, Mackowski, Mia, Koukakis, Reija, McVige, Jennifer Williams

“…Erenumab, a fully human monoclonal antibody targeting the calcitonin gene‐related peptide receptor, is efficacious and safe for prevention of attacks of…”
Get full text

Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis by Kitamura, Shigekazu, Takeshima, Takao, Yui, Daishi, da Silva Lima, Gabriel Paiva, Koukakis, Reija, Peng, Cheng, Yoshida, Ryuji, Numachi, Yotaro, Hasebe, Miki

“…Introduction Erenumab, a fully human monoclonal antibody against the calcitonin gene-related peptide receptor, is approved in Japan for the prevention of adult…”
Get full text

Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab by Köhne, Claus-Henning, Karthaus, Meinolf, Mineur, Laurent, Thaler, Josef, Van den Eynde, Marc, Gallego, Javier, Koukakis, Reija, Berkhout, Marloes, Hofheinz, Ralf-Dieter

“…Objective Data from a trial of first-line panitumumab plus FOLFIRI (folinic acid, infusional 5-fluorouracil and irinotecan) in metastatic colorectal cancer…”
Get full text

Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer by Douillard, Jean-Yves, Siena, Salvatore, Peeters, Marc, Koukakis, Reija, Terwey, Jan-Henrik, Tabernero, Josep

“…Abstract Background Tumour shrinkage (TS) increases the possibility of resection in metastatic colorectal cancer (mCRC) and may improve tumour-related…”
Get full text

Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials by Peeters, Marc, Price, Timothy, Taieb, Julien, Geissler, Michael, Rivera, Fernando, Canon, Jean-Luc, Pentheroudakis, George, Koukakis, Reija, Burdon, Peter, Siena, Salvatore

“…Background Data from two trials of panitumumab in metastatic colorectal cancer (mCRC) were retrospectively analysed to investigate the effects of primary…”
Get full text

A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer by Heinemann, Volker, Rivera, Fernando, O'Neil, Bert H, Stintzing, Sebastian, Koukakis, Reija, Terwey, Jan-Henrik, Douillard, Jean-Yves

“…Abstract Background Head-to-head trials comparing first-line epidermal growth factor receptor inhibitor (EGFRI) versus vascular endothelial growth factor…”
Get full text

Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials by Koukakis, Reija, Gatta, Francesca, Hechmati, Guy, Siena, Salvatore

“…Purpose Epidermal growth factor receptor inhibitors such as panitumumab are associated with characteristic skin toxicities. We summarise data from three…”
Get full text

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer by Peeters, Marc, Oliner, Kelly S, Price, Timothy J, Cervantes, Andrés, Sobrero, Alberto F, Ducreux, Michel, Hotko, Yevhen, André, Thierry, Chan, Emily, Lordick, Florian, Punt, Cornelis J A, Strickland, Andrew H, Wilson, Gregory, Ciuleanu, Tudor E, Roman, Laslo, Van Cutsem, Eric, He, Pei, Yu, Hua, Koukakis, Reija, Terwey, Jan-Henrik, Jung, Andre S, Sidhu, Roger, Patterson, Scott D

“…We evaluated the influence of RAS mutation status on the treatment effect of panitumumab in a prospective-retrospective analysis of a randomized, multicenter…”
Get full text

Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials by Modest, Dominik Paul, Rivera, Fernando, Bachet, Jean‐Baptiste, Braud, Filippo, Pietrantonio, Filippo, Koukakis, Reija, Demonty, Gaston, Douillard, Jean‐Yves

“…Panitumumab is approved for RAS wild‐type metastatic colorectal cancer and was evaluated in Phase III (PRIME, NCT00364013) and Phase II (PEAK, NCT00819780)…”
Get full text

Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials by Taieb, Julien, Rivera, Fernando, Siena, Salvatore, Karthaus, Meinolf, Valladares-Ayerbes, Manuel, Gallego, Javier, Geissler, Michael, Koukakis, Reija, Demonty, Gaston, Peeters, Marc

“…Purpose To report exploratory analyses of early tumour shrinkage (ETS) and depth of response (DpR) in patients with RAS wild-type (WT) metastatic colorectal…”
Get full text

Efficacy of erenumab in chronic migraine patients with and without ictal allodynia by Lipton, Richard B, Burstein, Rami, Buse, Dawn C, Dodick, David W, Koukakis, Reija, Klatt, Jan, Cheng, Sunfa, Chou, Denise E

“…Ictal cutaneous allodynia, common in chronic migraine, is associated with reduced responses to acute treatment with triptans. Allodynia's impact on the…”
Get more information

Impact of primary tumour location (PTL) on outcomes in patients (pts) with metastatic colorectal cancer (mCRC) undergoing first-line panitumumab (Pmab) + FOLFIRI treatment by Karthaus, Meinolf, Van Den Eynde, Marc, Mineur, Laurent, Thaler, Josef, Koukakis, Reija, Berkhout, Marloes, Gallego, Javier

“…Abstract only 820 Background: Prognosis in pts with mCRC is affected by PTL; PTL may also affect the activity of the epidermal growth factor receptor inhibitor…”
Get full text

Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies by Boeckx, Nele, Koukakis, Reija, Op de Beeck, Ken, Rolfo, Christian, Van Camp, Guy, Siena, Salvatore, Tabernero, Josep, Douillard, Jean-Yves, André, Thierry, Peeters, Marc

“…The results from the retrospective analyses of data from 4 phase III randomized panitumumab trials showed a worse prognosis for patients with right- versus…”
Get full text

Clinical practice use of panitumumab combined with chemotherapy in patients with wild-type RAS metastatic colorectal cancer by Hebart, Holger Frithjof, Tomasek, Jiri, Csõszi, Tibor, Koukakis, Reija, Kafatos, George, Kuhn, Anja, Björklöf, Katja, Buchler, Tomas

“…Abstract only 852 Background: This study aimed to understand panitumumab (pmab) use in clinical practice for patients with wild-type RAS metastatic colorectal…”
Get full text

Characteristics and response outcomes of long-term survivors in studies of first-line panitumumab for metastatic colorectal cancer by Köhne, Claus-Henning, Peeters, Marc, Carrato, Alfredo, Coriat, Romain, Rivera, Fernando, Koukakis, Reija, Demonty, Gaston, Geissler, Michael

Get full text

Rechallenge with EGFR inhibitors in patients with metastatic colorectal cancer: effect on outcomes by Salvatore, Siena, George, Pentheroudakis, Gerald, Prager, Andrea, Sartore-Bianchi, Aziz, Zaanan, Jean-Yves, Douillard, Jorge, Aparicio, Reija, Koukakis, Gaston, Demonty, Julien, Taieb

Get full text

Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC by Hebart, Holger, Kiehl, Michael, Tomasek, Jiri, Csoszi, Tibor, Koukakis, Reija, Kafatos, George, Kuhn, Anja, Bjorklof, Katja, Demonty, Gaston, Buchler, Tomas

“…Introduction This study aimed to better understand panitumumab use in real-life clinical practice in first- and second-line treatment of metastatic colorectal…”
Get full text

Impact of primary tumour location on response and resection outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line treatment by Peeters, Marc, Price, Timothy, Taieb, Julien, Geissler, Michael, Rivera, Fernando, Canon, Jean-Luc, Koukakis, Reija, Burdon, Peter, Siena, Salvatore

Get full text

Survival outcomes in patients (pts) with KRAS/NRAS ( RAS ) wild-type (WT) metastatic colorectal cancer (mCRC) and non-liver-limited disease (non-LLD): Data from the PRIME study by Douillard, Jean-Yves, Tabernero, Josep, Siena, Salvatore, Peeters, Marc, Koukakis, Reija, Terwey, Jan-Henrik, Sidhu, Roger

“…Abstract only…”
Get full text